GleamWall
中文EN

MLYS Mineralys Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1933414 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-115.9%
TTM EPS YoY-47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-68.5%
ROA-60.2%
ROIC (approx.)-80.9%
Asset turnover—

Leverage & solvency

Liabilities / assets20.1%
Debt / equity0.00x
Current ratio11.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-35.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$132.01M$168.58M
SG&A expense$38.59M$23.82M
Operating income-$170.60M-$192.40M
Income tax$0—
Net income-$154.65M-$177.81M
EBITDA-$170.54M-$192.36M
EPS (basic)-2.29-3.66
EPS (diluted)-2.29-3.66
Weighted avg. shares (diluted)67.66M48.54M
Balance sheet
Cash & equivalents$172.92M$114.09M
Current assets$661.39M$205.35M
PP&E, net$38,000$53,000
Total assets$661.81M$205.90M
Current liabilities$15.11M$14.65M
Total liabilities$15.11M$14.65M
Shareholders' equity$646.69M$191.26M
Shares outstanding81.54M49.82M
Cash flow statement
Operating cash flow-$142.42M-$166.31M
Capital expenditure$15,000$96,000
Free cash flow-$142.43M-$166.41M
Investing cash flow-$389.75M$114.96M
Financing cash flow$591.00M$116.14M
Depreciation & amortization$59,000$43,000
Stock-based compensation$19.32M$11.34M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.